Comparative clinical features of stage A1 and stage A2 prostate cancers. Is the concept of stage A changing from the current status?
We surveyed the comparative clinical features of patients with stage A1 and stage A2 prostate cancer. Preoperatively, prostate specific antigen (PSA) level was elevated in 50.0% of stage A2 patients as compared to 18.2% of stage A1 patients. Compared to low positivity of prostatic acid phosphatase in 12.5% of stage A2 and in 0% of stage A1, PSA was more sensitive to the presence of incidental carcinoma. During the observation period (mean 35.7 months) no stage A patient died of cancer. No evidence of the disease showed significantly higher rate, and death without cancer was significantly lower in stage A1.
Kunimi
K
K
Department of Urology, Kanazawa University, Japan.
Amano
T
T
Lee
S W
SW
Fuse
H
H
Uchibayashi
T
T
Miyazaki
K
K
Ohkawa
M
M
D000135:Acid Phosphatase / Q000097:blood*; D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology* / Q000628:therapy; D000368:Aged; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies
D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen